Cipro XR (Ciprofloxacin, BAYQ3939)

DRUG4 trials

Sponsors

Bayer

Conditions

Urinary Tract InfectionUrinary Tract Infections

Phase 3

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

CompletedNCT00668122

BayerUrinary Tract Infection

Start: 2004-03-31End: 2006-01-31Updated: 2009-06-30

Phase 4

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

CompletedNCT00481689

BayerUrinary Tract Infections

Start: 2004-05-31End: 2005-09-30Updated: 2009-06-26

A Phase IV Study of Cipro XR in Uncomplicated UTI

CompletedNCT00663806

BayerUrinary Tract Infections

Start: 2003-02-28End: 2003-07-31Updated: 2014-12-02

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

CompletedNCT00676533

BayerUrinary Tract Infection

Start: 2003-06-30End: 2004-01-31Updated: 2013-10-14